Sanofi SA vs Invesco Solar ETF — how do they compare? Sanofi SA trades at $40.14 (market cap $95.18B), while Invesco Solar ETF trades at $43.37 (market cap $894.08M). The key difference: Sanofi SA is far larger — about 106.5× Invesco Solar ETF's market cap, and Sanofi SA pays a 6.01% dividend while Invesco Solar ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Invesco Solar ETF for 34 Days on average.
| SNY | TAN | |
|---|---|---|
Market Cap | $95.18B | $894.08M |
Volume | 2,995,646 | 370,994 |
Sector | Health | Sector/Thematic |
52-Week High | $52.34 | $73.95 |
52-Week Low | $39.51 | $43.00 |
Typical Hold Time | 94 Days | 34 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
TAN (Invesco Solar ETF) is trading at $43.53, down 1.96% amid sector-wide pressure from high borrowing costs impacting solar project financing. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from solar industry volatility, price deflation, and margin erosion, having underperformed the S&P 500 by 112% over five years according to Seeking Alpha analysis from August 2026.
Outlook remains challenging with persistent sector headwinds including interest rate sensitivity and market saturation risks. Investment opportunity exists in long-term renewable energy transition, but requires tolerance for high volatility and deeper drawdowns compared to traditional energy ETFs. Key risks include policy uncertainty, grid adaptation costs, and competitive pressure from broader clean energy alternatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →